Platycodin D3

Platycodin D3 is a triterpenoid saponin that can be found in Platycodon grandiflorum. Platycodin D3 exhibits multiple activities including anti-inflammation, regulation of airway mucus secretion, improvement of asthmatic airway inflammation and remodeling, and inhibition of hepatitis C virus (HCV) replication. The IC₅₀ value of Platycodin D3 against HCV NS5B RNA-dependent RNA polymerase is 8 μg/mL. Platycodin D3 can be used in studies related to asthma, hepatitis C virus infection and inflammatory diseases^[1][2][3][4]. In Vitro:Platycodin D3 inhibits the activity of HCV NS5B RdRp with an IC₅₀ of 8 μg/mL, and does not inhibit the activity of HCV NS3/4A protease^[1].
Platycodin D3 (72 h) inhibits RNA replication of HCV genotype 1b in Huh7 replicon cells, with an EC₅₀ of 2.33 μg/mL and a CC₅₀ of 100 μg/mL in Huh7 cells, indicating low cytotoxicity^[1].
Platycodin D3 (48 h) inhibits HCV genotype 2a (JFH1) RNA replication in infected Huh7 cells, with an EC₅₀ of 27 μg/mL^[1].
Platycodin D3 (0.5-5 μg/mL; 3 days) dose-dependently inhibits the expression of HCV NS5A protein in Huh7 cells harboring the subgenomic replicon of HCV genotype 1b^[1].
Platycodin D3 (0-60 μM; 24 h) dose-dependently inhibits nitric oxide production in RAW 264.7 cells activated by LPS (HY-D1056) and IFN-γ, with an IC₅₀ of 55 μM, and shows no cytotoxicity at concentrations up to 60 μM^[2].
Platycodin D3 (20-50 μM; 16-24 h) dose-dependently inhibits iNOS protein expression and upregulates TNF-α mRNA expression in RAW 264.7 cells activated by LPS and IFN-γ^[2].
Platycodin D3 (1-100 μM; 30 min pre-incubation) inhibits the production and secretion of MUC5AC mucin in PMA (HY-18739)-induced NCI-H292 cells^[3]. In Vivo:Platycodin D3 (20-80 mg/kg/d for 8 weeks) reduces airway hyperresponsiveness, inflammatory responses, and pathological damage in asthmatic mice in a dose-dependent manner in vivo^[4].